Neurocognitive impairment and dementia in mood disorders

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 19, Issue 4, 2007, Pages 373-382

  Pfennig, Andrea ^a,b   Littmann, Eckhard ^a   Bauer, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; ATTENTION; CAUSAL ATTRIBUTION; CLINICAL FEATURE; COGNITION; COMORBIDITY; DEMENTIA; DEPRESSION; DEPTH PERCEPTION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FUNCTIONAL ASSESSMENT; HUMAN; MEMORY; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEMANTIC MEMORY;

EID: 36348983323     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2007.19.4.373     Document Type: Review

References (89)

1. Hargrave R, Reed B, Mungas D: Depressive syndromes and functional disability in dementia. J Geriatr Psychiatry Neurol 2000; 13:72-77
2. Tohen M, Zarate CA, Jr, Hennen J, et al: The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003; 160:2099-2107
3. Ferrier IN: Treatment of major depression: is improvement enough? J Clin Psychiatry 1999; 60(suppl 6):10-14
4. MacQueen GM, Young LT, Joffe RT: A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr Scand 2001; 103:163-170
5. Mintz J, Mintz LI, Arruda MJ, et al: Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49:761-768
6. Judd LL, Kessler RC, Paulus MP, et al: Comorbidity as a fundamental feature of generalized anxiety disorders: results from the national comorbidity study (NCS). Acta Psychiatr Scand Suppl 1998; 393:6-11
7. Green MF, Kern RS, Braff DL, et al: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000; 26:119-136
8. Fujii DE, Wylie AM, Nathan JH: Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness. Schizophr Res 2004; 69:67-73
9. Depp CA, Davis CE, Mittal D, et al: Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder. J Clin Psychiatry 2006; 67:215-221
10. Nierenberg AA, Keefe BR, Leslie VC, et al: Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60:221-225
11. Paykel ES: Remission and residual symptomatology in major depression. Psychopathology 1998; 31:5-14
12. Martinez-Aran A, Vieta E, Reinares M, et al: Cognitive function across manic or hypomanic, depressed, and eu thymic states in bipolar disorder. Am J Psychiatry 2004; 161:262-270
13. Goodwin FK, Jamison KR: Manic-Depressive Illness. New York, Oxford University Press, 1990
14. Reischies FM, Neu P: Comorbidity of mild cognitive disorder and depression-a neuropsychological analysis. Eur Arch Psychiatry Clin Neurosci 2000; 250:186-193
15. Thompson JM, Gallagher P, Hughes JH, et al: Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005; 186:32-40
16. Quraishi S, Frangou S: Neuropsychology of bipolar disorder: a review. J Affect Disord 2002; 72:209-226
17. Martinez-Aran A, Vieta E, Colom F, et al: Neuropsychological performance in depressed and euthymic bipolar patients. Neuropsychobiology 2002; 46(suppl 1):16-21
18. Balanza-Martinez V, Tabares-Seisdedos R, Selva-Vera G, et al: Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patients: a 3-year follow-up study. Psychother Psychosom 2005; 74:113-119
19. Robinson LJ, Ferrier IN: Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord 2006; 8:103-116
20. Soares JC, Mann JJ: The anatomy of mood disorders-review of structural neuroimaging studies. Biol Psychiatry 1997; 41:86-106
21. Blumberg HP, Kaufman J, Martin A, et al: Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry 2003; 60:1201-1208
22. Lopez-Larson MP, DelBello MP, Zimmerman ME, et al: Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol Psychiatry 2002; 52:93-100
23. Strakowski SM, DelBello MP, Sax KW, et al: Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Arch Gen Psychiatry 1999; 56:254-260
24. Hirayasu Y, Shenton ME, Salisbury DF, et al: Subgenual cingulate cortex volume in first-episode psychosis. Am J Psychiatry 1999; 156:1091-1093
25. Blumberg HP, Leung HC, Skudlarski P, et al: A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry 2003; 60:601-609
26. Petersen RC, Smith GE, Ivnik RJ, et al: Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273:1274-1278
27. Petersen RC, Smith GE, Waring SC, et al: Aging, memory, and mild cognitive impairment. Int Psychogeriatr 1997; 9(suppl 1):65-69
28. DeCarli C: Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003; 2:15-21
29. Busse A, Bischkopf J, Riedel-Heller SG, et al: Mild cognitive impairment: prevalence and predictive validity according to current approaches. Acta Neurol Scand 2003; 108:71-81
30. Busse A, Bischkopf J, Riedel-Heller SG, et al: Mild cognitive impairment: prevalence and incidence according to different diagnostic criteria, results of the leipzig longitudinal study of the aged (LEILA75+). Br J Psychiatry 2003; 182:449-454
31. Morris JC, Storandt M, Miller JP, et al: Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58:397-405
32. Collie A, Maruff P, Shafiq-Antonacci R, et al: Memory decline in healthy older people: implications for identifying mild cognitive impairment. Neurology 2001; 56:1533-1538
33. Collie A, Maruff P: An analysis of systems of classifying mild cognitive impairment in older people. Aust N Z J Psychiatry 2002; 36:133-140
34. Jorm AF: History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry 2001; 35:776-781
35. Kessing LV, Nilsson FM: Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 2003; 73:261-269
36. Kessing LV, Andersen PK: Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004; 75:1662-1666
37. Gatz JL, Tyas SL, St JP, et al: Do depressive symptoms predict Alzheimer's disease and dementia? J Gerontol A Biol Sci Med Sci 2005; 60:744-747
38. Modrego PJ, Ferrandez J: Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol 2004; 61:1290-1293
39. Lee AL, Ogle WO, Sapolsky RM: Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 2002; 4:117-128
40. Kempermann G: Regulation of adult hippocampal neurogenesis-implications for novel theories of major depression. Bipolar Disord 2002; 4:17-33
41. Kempermann G, Kronenberg G: Depressed new neurons-adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry 2003; 54:499-503
42. Sapolsky RM: The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000; 48:755-765
43. Sapolsky RM: Glucocorticoids and hippocampal atrophy in neuropsychiatrie disorders. Arch Gen Psychiatry 2000; 57:925-935
44. Lemaire V, Koehl M, Le MM, et al: Prenatal stress produces learning deficits associated with an inhibition of neurogenesis in the hippocampus. Proc Natl Acad Sci U S A 2000; 97:11032-11037
45. Rapp MA, Schnaider-Beeri M, Grossman HT, et al: Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006; 63:161-167
46. Sapolsky RM: Stress and plasticity in the limbic system. Neurochem Res 2003; 28:1735-1742
47. Manji HK, Quiroz JA, Sporn J, et al: Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53:707-742
48. Christensen MV, Kyvik KO, Kessing LV: Cognitive function in unaffected twins discordant for affective disorder. Psychol Med 2006; 36:1119-1129
49. Glahn DC, Bearden CE, Niendam TA, et al: The feasibility of neuropsychological endophenotypes in the search for genes associated with bipolar affective disorder. Bipolar Disord 2004; 6:171-182
50. Crowe SF, Hoogenraad K: Differentiation of dementia of the Alzheimer's type from depression with cognitive impairment on the basis of a cortical versus subcortical pattern of cognitive deficit. Arch Clin Neuropsychol 2000; 15:9-19
51. Marin DB, Sewell MC, Schlechter A: Alzheimer's disease. Accurate and early diagnosis in the primary care setting. Geriatrics 2002; 57:36-40
52. Wells CE: Pseudodementia. Am J Psychiatry 1979; 136:895-900
53. Doniger GM, Dwolatzky T, Zucker DM, et al: Computerized cognitive testing battery identifies mild cognitive impairment and mild dementia even in the presence of depressive symptoms. Am J Alzheimers Dis Other Demen 2006; 21:28-36
54. Kessler J, Calabrese P, Kalbe E: Demtect: Ein neues screening-verfahren zur Unterstützung der demenzdiagnostik. Psycho 2000; 26:343-347
55. Perneczky: Kurze kognitive Tests: Validierung dreier neuropsychologischer Werkzeuge in der Diagnostik der leichten kognitiven Beeinträchtigung und der leicht- bis mittelgradigen Demenz bei Alzheimer-Krankheit. Dissertation München 2003
56. Kalbe E, Kessler J, Calabrese P, et al: DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 2004; 19:136-143
57. Esteban-Santillan C, Praditsuwan R, Ueda H, et al: Clock drawing test in very mild Alzheimer's disease. J Am Geriatr Soc 1998; 46:1266-1269
58. Morris JC, Heyman A, Mohs RC, et al: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39:1159-1165
59. Oswald WD, Fleischmann UM: Psychometrics in aging and dementia: advances in geropsychological assessments. Arch Gerontol Geriatr 1985; 4:299-309
60. Lamberty GJ, Bieliauskas LA: Distinguishing between depression and dementia in the elderly: a review of neuropsychological findings. Arch Clin Neuropsychol 1993; 8:149-170
61. Jean L, Simard M, van Reekum R, et al: Differential cognitive impairment in subjects with geriatric depression who will develop Alzheimer's disease and other dementias: a retrospective study. Int Psychogeriatr 2005; 17:289-301
62. Tierney MC, Szalai JP, Snow WG, et al: Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996; 46:661-665
63. Blackwell Scientific AD, Sahakian BJ, Vesey R, et al: Detecting dementia: novel neuropsychological markers of preclinical Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17:42-48
64. Swainson R, Hodges JR, Galton CJ, et al: Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks. Dement Geriatr Cogn Disord 2001; 12:265-280
65. Buerger K, Zinkowski R, Teipel SJ, et al: Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry 2003; 160:376-379
66. Dawson R, Lavori PW, Coryell WH, et al: Maintenance strategies for unipolar depression: an observational study of levels of treatment and recurrence. J Affect Disord 1998; 49:31-44
67. Kennedy N, Paykel ES: Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord 2004; 80:135-144
68. McIntyre RS, O'Donovan C: The human cost of not achieving full remission in depression. Can J Psychiatry 2004; 493(suppl 1):10S-16S
69. Manji HK, Moore GJ, Rajkowska G, et al: Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5:578-593
70. Frank E, Kupfer DJ, Perel JM, et al: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093-1099
71. Fava GA, Rafanelli C, Grandi S, et al: Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998; 155:1443-1445
72. Segal Z, Vincent P, Levitt A: Efficacy of combined, sequential and crossover psychotherapy and pharmacotherapy in improving outcomes in depression. J Psychiatry Neurosci 2002; 27:281-290
73. Pilcher HR: Drug research: the ups and downs of lithium. Nature 2003; 425:118-120
74. Wang JF, Azzam JE, Young LT: Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 2003; 116:485-489
75. Chen G, Zeng WZ, Yuan PX, et al: The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72:879-882
76. Yuan PX, Huang LD, Jiang YM, et al: The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001; 276:31674-31683
77. Du J, Gray NA, Falke C, et al: Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating ampa glutamate receptor subunit glurl synaptic expression. Ann N Y Acad Sci 2003; 1003:378-380
78. Gould TD, Manji HK: Signaling networks in the pathophysiology and treatment of mood disorders. J Psychosom Res 2002; 53:687-697
79. Jope RS: Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24:441-443
80. Nonaka S, Chuang DM: Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998; 9:2081-2084
81. Hashimoto R, Hough C, Nakazawa T, et al: Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002; 80:589-597
82. MacQueen GM, Young LT, Galway TM, et al: Backward masking task performance in stable, euthymic out-patients with bipolar disorder. Psychol Med 2001; 31:1269-1277
83. Bauer M, Aida M, Priller J, et al: Implications of the Neuroprotective Effects of Lithium for the Treatment of Bipolar and Neurodegenerative Disorders. Pharmacopsychiatry 2003; 36(suppl 3:250-254
84. Engelsmann F, Katz J, Ghadirian AM, et al: Lithium and memory: a long-term follow-up study. J Clin Psychopharmacol 1988; 8:207-212
85. Letendre S, et al: Lithium improves HIV-associated neurocognitive impairment. AIDS 2006; 20:1885-1888
86. Moore GJ, Bebchuk JM, Wilds IB, et al: Lithium-induced increase in human brain grey matter. Lancet 2000; 356:1241-1242
87. Moore GJ, Bebchuk JM, Hasanat K, et al: Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000; 48:1-8
88. Silverstone PH, Wu RH, O'Donnell T, et al: Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 2003; 18:73-79
89. Li LM, Cendes F, Antel SB, et al: Prognostic value of proton magnetic resonance spectroscopic imaging for surgical outcome in patients with intractable temporal lobe epilepsy and bilateral hippocampal atrophy. Ann Neurol 2000; 47:195-200